0.25 mg, tablets
Alprazolamum
Afobam and Frontin are different trade names for the same drug.
The active substance of this drug, alprazolam, belongs to a group of drugs called benzodiazepine derivatives (drugs with anxiolytic activity).
Afobam is indicated for the treatment of symptoms of anxiety disorders in adults, only in situations where the symptoms are severe, prevent normal functioning, or are very troublesome for the patient. This drug is intended for short-term use only.
Afobam should not be used in children and adolescents under 18 years of age.
Before starting treatment with Afobam, you should discuss it with your doctor or pharmacist.
Like other benzodiazepines, Afobam may cause anterograde amnesia, which occurs a few hours after taking the drug. In such a case, the patient should have the opportunity for uninterrupted sleep for 7-8 hours.
Episodes of mania and hypomania associated with the use of alprazolam have been reported in patients with depression.
Before a planned surgical procedure, the doctor should be informed about the use of Afobam.
Afobam should not be used in children and adolescents under 18 years of age.
You should tell your doctor or pharmacist about all the drugs you are currently taking or have recently taken, as well as any drugs you plan to take.
Afobam with alcohol
Alcohol should not be consumed during the use of Afobam.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor or pharmacist before using this drug.
This drug should not be used during pregnancy.
If the drug is used during pregnancy or if you become pregnant while using alprazolam, you should be examined for potential fetal risk.
If it is necessary to administer the drug in the last period of pregnancy, you should avoid high doses and monitor the newborn.
Benzodiazepines pass into breast milk in small amounts. Afobam should not be used during breastfeeding.
Afobam may impair psychomotor skills. Before using Afobam, you should familiarize yourself with current local traffic laws. While using Afobam, you should not drive vehicles or operate machines.
If you have been diagnosed with intolerance to some sugars, you should contact your doctor before taking this drug.
This drug contains less than 1 mmol of sodium (23 mg) per tablet, which means the drug is considered "sodium-free".
This drug should always be taken according to the doctor's or pharmacist's instructions. In case of doubts, you should consult a doctor or pharmacist.
Afobam is available in the following doses: 0.25 mg, 0.5 mg, 1 mg.
Treatment should be as short as possible. The doctor should frequently assess the patient's condition and the need to extend treatment, especially if the severity of the symptoms decreases and may not require pharmacological treatment. The total treatment time should not exceed 2-4 weeks. Long-term treatment is not recommended.
When starting treatment, the doctor will inform you about the limited duration of therapy, the gradual reduction of the dose during withdrawal, and the possibility of withdrawal reactions.
During the use of benzodiazepines, including Afobam, dependence and emotional or physical dependence may develop. This risk may increase with the dose and duration of treatment, so the lowest effective dose should be used for the shortest possible time, and the need for continued treatment should be frequently assessed with the doctor.
Recommended dose
The dose is determined by the doctor based on the severity of symptoms and the patient's individual response to treatment. If severe side effects occur after administration of the initial dose, the doctor may decide to reduce the dose.
Symptomatic treatment of anxiety disorders
The recommended initial dose is 0.25 mg or 0.5 mg, taken three times a day. Depending on the patient's response to treatment, the doctor may increase the dose to a maximum daily dose of 4 mg, taken in smaller divided doses throughout the day.
Afobam should not be used in children and adolescents under 18 years of age.
Use in patients with severe liver failure is contraindicated.
The recommended initial dose is 0.25 mg, taken two or three times a day. Depending on the tolerance of treatment, the doctor may decide to gradually increase the dose if necessary. If side effects occur, the doctor will decide to reduce the initial dose.
The tablet can be divided into equal doses.
In case of taking more tablets than recommended, ataxia (uncoordinated movements), drowsiness, speech disorders, coma, and respiratory depression may occur. If you notice any worrying symptoms, you should immediately consult a doctor.
You should not take a double dose to make up for a missed dose.
You should not stop using this drug without consulting your doctor.
Since the treatment is only symptomatic, after its discontinuation, the symptoms may return.
The doctor will decide to gradually reduce the dose.
If you have any further doubts about the use of this drug, you should consult a doctor or pharmacist.
Like all drugs, this drug may cause side effects, although they do not occur in everyone.
If any of the following side effects persist or become troublesome, you should consult a doctor. The occurrence of some side effects depends on the individual sensitivity of the patient and the administered dose. Side effects are usually observed at the beginning of treatment and disappear as treatment continues or after the dose is reduced.
In clinical trials and after the drug was introduced to the market, the following frequency of side effects was reported:
Common (may occur in up to 1 in 10 patients):
In addition, especially in patients taking other psychotropic drugs, with mental disorders, or abusing alcohol, a paradoxical reaction may occur, such as anxiety.
Other side effects have been observed rarely or very rarely: motor disorders, epilepsy, psychotic symptoms, changes in self-perception, agranulocytosis (significant decrease in granulocyte count), allergic and anaphylactic reactions (severe allergic reactions).
Benzodiazepines may cause physical and psychological dependence. After physical dependence has developed, sudden discontinuation of alprazolam may cause withdrawal symptoms, such as headache, muscle pain, increased anxiety, feeling of tension, agitation, disorientation, irritability, changes in perception of the environment or oneself, impaired hearing, stiffness, and tingling of limbs, hypersensitivity to light, noise, and touch, hallucinations, and seizures. These symptoms are usually more severe in patients treated for a long time, with high doses of benzodiazepines, and in the case of sudden or rapid discontinuation of the drug.
If you experience any side effects, including any side effects not listed in this leaflet, you should tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
tel.: + 48 (22) 49 21 301
fax: + 48 (22) 49 21 309
website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help gather more information on the safety of the drug.
Do not store above 25°C.
The drug should be stored in a place out of sight and reach of children.
Do not use this drug after the expiration date stated on the packaging. The expiration date refers to the last day of the specified month.
Drugs should not be disposed of in the sewage system or household waste containers. You should ask your pharmacist how to dispose of unused drugs. This will help protect the environment.
The active substance of the drug is 0.25 mg of alprazolam in one tablet.
The other ingredients are: lactose monohydrate, microcrystalline cellulose, cornstarch, magnesium stearate, sodium lauryl sulfate, anhydrous colloidal silica.
Appearance:
White or yellowish-white, oblong, biconvex tablets with a dividing line on one side and the inscription "E" and "311" on the other side.
The tablets can be divided into equal doses.
Packaging:
A brown glass bottle with a white plastic cap, in a cardboard box, with an informational leaflet.
The packaging contains 30 or 100 tablets.
To obtain more detailed information, you should contact the marketing authorization holder or parallel importer.
Egis Gyógyszergyár Zrt.
Keresztúri út 30-38.
H-1106 Budapest
Hungary
Egis Gyógyszergyár Zrt.
Mátyás király ú. 65.
H-9900 Körmend
Hungary
Egis Gyógyszergyár Zrt.
Bökényföldi út 118-120.
1165 Budapest
Hungary
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Polfarmex S.A.
ul. Józefów 9
99-300 Kutno
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Marketing authorization number in Hungary, the country of export: OGYI-T-05967/01
OGYI-T-05967/02
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.